Genomeditech (Shanghai) Co.,Ltd.
Order: 021-68455258/50432826/50432825
Toll-free: 400 627 9288
Email: service@genomeditech.com

Anti-VEGF×PD-L1 hIgG1 Bispecific Antibody (pumitamig)

Product information

GM-88169AB-10	10 μg
GM-88169AB-100	100 μg
GM-88169AB-1000	1 mg

Antibody Information

Species Reactivity	Human
Clone	pumitamig
Source/Isotype	Human IgG1(L234A/L235A) ,Kappa
Application	Block assay
Target	Detects VEGF & PD-L1
Gene	VEGF & PD-L1
Other Names	VEGF: KDR,CD309,FLK1,VEGF R2 PD-L1: CD274,B7-H1,PDCD1L1,PDCD1LG1,B7H1, PDL1, hPD-L1
Gene ID	VEGF: 7422 (Human) PD-L1: 29126 (Human)
Background	Pumitamig (BNT327) is a bispecific antibody drug that targets PD-L1 and VEGF-A in a research context derived from the unmet need that exists in the treatment of solid tumors such as small-cell carcinoma (SCLC) . As a highly malignant subtype of lung cancer, SCLC has the characteristics of rapid growth and easy metastasis. About 70% of patients are in an extensive stage when they are diagnosed. Traditional treatment methods have limited effect, and the 5-year survival rate has been low for a long time. PD-L1 promotes immune escape by inhibiting immune cell function in the tumor microenvironment, while VEGF-A supports tumor growth and metastasis by driving tumor angiogenesis. By simultaneously blocking these two key targets, Pumitamig aims to restore effector T cell activity, inhibit tumor angiogenesis, and break the tumor immune escape mechanism to achieve a multidimensional attack on tumors.
Storage	Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.
Formulation	Phosphate-buffered solution, pH 7.2-7.4.
Endotoxin	< 1 EU/mg, determined by LAL gel clotting assay

Data Examples

Block assay

Anti-VEGF×PD-L1 hIgG1 Bispecific Antibody (pumitamig) (Catalog # GM-88169AB) inhibits H_VEGF Reporter 293 Cell Line (Catalog # GM-C09057) Luminescence induced by Human VEGF165. IC50 for this effect is 0.08775 μg/mL.



	H_VEGF Reporter 293 Cell line
IC50	0.08775

Fig. assay